Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2000-6-8
pubmed:abstractText
To assess the feasibility and tolerance of neoadjuvant and concomitant estramustine phosphate and vinblastine (EV) with high-dose three-dimensional conformal radiotherapy (3D-CRT) for patients with unfavorable-risk prostate cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0732-183X
pubmed:author
pubmed:issnType
Print
pubmed:volume
18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1936-41
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:10784635-Administration, Oral, pubmed-meshheading:10784635-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:10784635-Combined Modality Therapy, pubmed-meshheading:10784635-Estramustine, pubmed-meshheading:10784635-Etoposide, pubmed-meshheading:10784635-Gastrointestinal Diseases, pubmed-meshheading:10784635-Humans, pubmed-meshheading:10784635-Injections, Intravenous, pubmed-meshheading:10784635-Male, pubmed-meshheading:10784635-Male Urogenital Diseases, pubmed-meshheading:10784635-Neoadjuvant Therapy, pubmed-meshheading:10784635-Prospective Studies, pubmed-meshheading:10784635-Prostate-Specific Antigen, pubmed-meshheading:10784635-Prostatic Neoplasms, pubmed-meshheading:10784635-Radiotherapy, Conformal, pubmed-meshheading:10784635-Radiotherapy Dosage, pubmed-meshheading:10784635-Risk Factors, pubmed-meshheading:10784635-Treatment Outcome, pubmed-meshheading:10784635-Vinblastine, pubmed-meshheading:10784635-Vindesine
pubmed:year
2000
pubmed:articleTitle
Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer.
pubmed:affiliation
Department of Radiation Oncology, Solid Tumor Service, Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. zelefskm@mskcc.org
pubmed:publicationType
Journal Article, Clinical Trial, Clinical Trial, Phase II